Skip to content
SurenoGet Sureno Browser
← Sureno News

New advice on puberty blockers for trans and gender-diverse children sets out who may benefit

What the draft recommends

The National Health and Medical Research Council (NHMRC) released its draft advice yesterday. It says puberty suppressants, also called puberty blockers, should be available to some young people under 18 with gender incongruence.

How the medicines work

Puberty suppressants temporarily reduce the hormonal signals that drive puberty, lowering the body’s production of oestrogen or testosterone. They have been used to treat early puberty since the 1980s and have been prescribed to transgender and gender-diverse young people for decades.

The treatment can delay changes such as a deeper voice or breast development, giving young people time to consider their options. When the medicines are stopped, hormonal signalling usually resumes and puberty can continue.

Most young people who begin suppressants later take gender-affirming hormones, either oestrogen or testosterone. Others stop the suppressants without starting hormones, and puberty resumes.

Understanding gender incongruence

Gender incongruence describes a difference between someone’s gender and the sex recorded at birth. It is not classified as a mental disorder. Gender dysphoria is different: it refers to significant distress that some people experience in relation to gender incongruence. The stated aim of puberty suppression is to delay unwanted changes that could cause distress.

Evidence, use and debate

The NHMRC says evidence about the long-term effects remains limited, while finding that potential benefits are likely to outweigh risks for some young people. Australia has no national tally of young people receiving puberty suppressants.

In July 2026, public health services reported 58 young people receiving the medicines in Western Australia and 77 in Queensland. Together, the 135 patients represented about 0.007% of the combined under-18 population of those states.

Restrictions have been introduced or proposed in the United Kingdom, Finland, Sweden, Argentina, Brazil, Turkey and parts of Canada. Many US states have banned the treatments for minors; New Zealand’s 2025 restrictions were overturned by its High Court last month.

The treatment has become a focus of wider disputes about transgender and gender-diverse people’s rights and identities. The article describes an international anti-gender movement, largely led by conservative, religious and right-wing groups, that has presented puberty suppression as a threat to children’s welfare, parental authority and traditional family structures.

Key points

  • The NHMRC says blockers should be available to some young people under 18 with gender incongruence.
  • The medicines delay puberty-related changes, and puberty usually resumes after treatment ends.
  • The council says long-term evidence is limited, but benefits may outweigh risks for some young people.
  • Public health services reported 135 patients receiving suppressants in Western Australia and Queensland in July 2026.
Read the original on The Conversation ↗

More news

Loading stories…